Barclays Forecasts Strong Price Appreciation for Fortrea (NASDAQ:FTRE) Stock

Key Points

• Barclays raised Fortrea’s price target to $26 from $23 and maintained an “overweight” rating, implying about 22% upside from the stock’s $21.25 price. However, the broader analyst consensus remains “Hold,” with an average target of $23.23.
• Fortrea beat quarterly expectations, reporting $0.28 in EPS versus $0.22 expected and revenue of $691.5 million versus $671.6 million forecast.
• The stock fell 8.2% in Friday trading despite the earnings beat, as investors weighed its negative 3.18% net margin, restructuring and balance-sheet challenges, and uncertainty around future profit growth.

Fortrea (NASDAQ:FTRE - Get Free Report) had its price objective raised by equities research analysts at Barclays from $23.00 to $26.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has an "overweight" rating on the stock. Barclays's price target would indicate a potential upside of 22.34% from the company's current price.

FTRE has been the subject of several other research reports. Mizuho increased their price objective on Fortrea from $13.00 to $16.00 and gave the company a "neutral" rating in a report on Monday, July 13th. Robert W. Baird set a $23.00 target price on shares of Fortrea in a report on Thursday, July 30th. UBS Group upped their price target on shares of Fortrea from $22.00 to $24.00 and gave the stock a "neutral" rating in a research report on Tuesday, October 20th. Evercore reiterated an "outperform" rating on shares of Fortrea in a research note on Wednesday, July 29th. Finally, Wall Street Zen raised shares of Fortrea from a "hold" rating to a "buy" rating in a research report on Saturday, October 10th. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Fortrea presently has a consensus rating of "Hold" and an average price target of $23.23.

Fortrea Stock Down 8.2%

Shares of NASDAQ:FTRE traded down $1.89 during midday trading on Friday, reaching $21.25. The company had a trading volume of 404,960 shares, compared to its average volume of 1,549,322. Fortrea has a 1-year low of $8.55 and a 1-year high of $26.16. The stock has a market cap of $2.02 billion, a PE ratio of -23.40, a P/E/G ratio of 0.62 and a beta of 1.93. The company has a quick ratio of 0.96, a current ratio of 0.96 and a debt-to-equity ratio of 1.98. The business's 50 day moving average price is $20.22 and its 200 day moving average price is $15.73.

Fortrea (NASDAQ:FTRE - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.22 by $0.06. The firm had revenue of $691.50 million during the quarter, compared to analysts' expectations of $671.57 million. Fortrea had a positive return on equity of 10.72% and a negative net margin of 3.18%. Research analysts forecast that Fortrea will post 0.86 EPS for the current fiscal year.

Insiders Place Their Bets

In other Fortrea news, CEO Anshul Thakral sold 99,869 shares of the firm's stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $19.16, for a total transaction of $1,913,490.04. Following the completion of the sale, the chief executive officer owned 316,797 shares of the company's stock, valued at $6,069,830.52. This trade represents a 23.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.73% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of FTRE. Financial Management Professionals Inc. acquired a new stake in shares of Fortrea during the third quarter worth $30,000. Ancora Advisors LLC bought a new position in Fortrea during the second quarter worth about $59,000. Allworth Financial LP raised its stake in Fortrea by 22.3% in the 2nd quarter. Allworth Financial LP now owns 3,923 shares of the company's stock worth $68,000 after purchasing an additional 716 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Fortrea in the 3rd quarter worth about $97,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in Fortrea in the 2nd quarter worth about $115,000.

Fortrea News Roundup

Here are the key news stories impacting Fortrea this week:

• Positive Sentiment: Fortrea reported third-quarter adjusted earnings of $0.28 per share, ahead of analyst expectations, while revenue reached $691.5 million versus the approximately $671.6 million consensus. Earnings also improved from $0.12 per share a year earlier. Fortrea Third-Quarter Earnings Results
• Positive Sentiment: Management raised its full-year 2026 adjusted EBITDA forecast to $210 million-$218 million, signaling better cost control and operating performance than previously expected. Full-year revenue is projected at $2.665 billion-$2.690 billion. Fortrea Raises EBITDA Outlook
• Neutral Sentiment: The earnings call emphasized the quarterly beat and improved EBITDA outlook, but investors are weighing those gains against Fortrea’s broader restructuring, execution and balance-sheet challenges. Fortrea Q3 Earnings Call Transcript
• Negative Sentiment: Despite exceeding quarterly estimates, Fortrea’s revised full-year earnings guidance appears to have disappointed investors or introduced uncertainty about the pace of profit growth. The company still reported a negative net margin of 3.18%, and the stock’s elevated valuation following its recovery from its 12-month low amplified the reaction. Fortrea 2026 Guidance

About Fortrea

Fortrea Holdings Inc is a global contract research organization (CRO) that provides services to pharmaceutical, biotechnology and medical device companies. The company helps clients plan, manage and execute clinical development programs, supporting the testing of new medicines and therapies from early-stage research through regulatory approval and post-approval activities.

Its services include Phase I through Phase IV clinical trials, clinical operations, patient recruitment and access, data management, biostatistics, medical monitoring, pharmacovigilance and regulatory support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.